Abstract Number: 1693 • 2018 ACR/ARHP Annual Meeting
Innate, Adaptive, and TNF-Superfamily Immune Pathways Inform a Lupus Disease Activity Immune Index That Characterizes Disease Activity in SLE
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease marked by immune dysregulation. A comprehensive but cost-effective tool to track relevant mediators of altered…Abstract Number: 2151 • 2018 ACR/ARHP Annual Meeting
The Impact of Obesity on SLE Disease Activity
Background/Purpose: Obesity is associated with increased disease severity in multiple autoimmune conditions, likely via formation of pro-inflammatory adipokines [1]. However, the role of obesity in…Abstract Number: 2505 • 2018 ACR/ARHP Annual Meeting
Sociodemographic Factors Are Predictors of Poorer Clinical Outcome Trajectories in Early Rheumatoid Arthritis: Results from the Singapore Early Arthritis Cohort
Background/Purpose: Variable outcomes in early rheumatoid arthritis (ERA) may be explained by heterogeneous latent disease activity trajectories, the predictors of which are not well defined.…Abstract Number: 2870 • 2018 ACR/ARHP Annual Meeting
Thresholds for Disease Activity Measures DAS28, CDAI, and RAPID3 Do Not Align with Clinical Practice Patterns of Rheumatoid Arthritis (RA) Disease Management Decisions
Background/Purpose: Treatment guidelines recommend using disease activity measures (DAMs) to guide RA therapy, but DAM use in real-world treatment decisions is not defined. We…Abstract Number: 92 • 2018 ACR/ARHP Annual Meeting
Lupus Nephritis Serum Induces Neutrophil Chemotaxis Towards Glomerular Endothelial Cells in Vitro
Title: Lupus Nephritis Serum Induces Neutrophil Chemotaxis towards Glomerular Endothelial Cells In Vitro Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic inflammatory disease associated with…Abstract Number: 491 • 2018 ACR/ARHP Annual Meeting
Cognitive Impairment Is Associated with Disease Activity in Patients with Rheumatoid Arthritis
Background/Purpose: Intact cognitive function is important for executing several tasks on day-to-day basis in people with chronic diseases, including rheumatoid arthritis (RA). A number of…Abstract Number: 906 • 2018 ACR/ARHP Annual Meeting
Defining the Gut Microbiome in Patients with ANCA-Associated Vasculitis
Background/Purpose:Although a link between gut microbiome and autoimmune diseases has been suggested, there is a gap in the understanding of the gut microbiome in ANCA-associated…Abstract Number: 1489 • 2018 ACR/ARHP Annual Meeting
“Continuous Reduction” in Serum RF Titers Predicts Low Disease Activity and Good Therapeutic Response in RA Patients Treated with TNF Inhibitors, but Does Not Relate to Clinical Outcomes during ABT Treatment
Background/Purpose: Relative change of serum RF titer has been reported to correlate with those of RA disease activity. However, it is debatable whether serum RF…Abstract Number: 1696 • 2018 ACR/ARHP Annual Meeting
Impact of Hurricane Maria on a Cohort of Systemic Lupus Erythematosus Patients from Puerto Rico
Background/Purpose: On September 20, 2017, Puerto Rico was devastated by Hurricane Maria causing severe damage to the Island infrastructure and essential services such as electricity,…Abstract Number: 2156 • 2018 ACR/ARHP Annual Meeting
Smoking Status Predicts Earlier SLICC Damage Index Progression in a Large SLE Cohort
Background/Purpose: Tobacco smoking predisposes to certain specific manifestations of systemic lupus erythematosus (SLE); however, less is known about smoking and cumulative organ damage in SLE.…Abstract Number: 2528 • 2018 ACR/ARHP Annual Meeting
A Multicenter Study Assessing the Efficacy and Safety of Repository Corticotropin Injection in Patients with Rheumatoid Arthritis: Preliminary Interim Data from the Open-Label Treatment Period
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disorder associated with chronic inflammation and commonly treated with disease-modifying anti-rheumatic drugs (DMARDs) and corticosteroids. Repository corticotropin injection…Abstract Number: 2871 • 2018 ACR/ARHP Annual Meeting
Comprehensive Provider Judgement Is a Significant Determinant of Major Therapeutic Change in Patients with Moderate to Severe Rheumatoid Arthritis
Background/Purpose: We have previously reported an evaluation of 941 US Veterans in the Veterans Affairs (VA) Rheumatoid Arthritis (RA) (VARA) registry that 559 (59%)…Abstract Number: 141 • 2018 ACR/ARHP Annual Meeting
Lymphocyte Activation Gene 3 Plasma Level Is Increased and Associated with Progression in Early Rheumatoid Arthritis
Background/Purpose: Lymphocyte activation gene 3 (LAG3) resembles CD4 and is a key checkpoint molecule leading to downregulation of T cell proliferation and antigen presentation via…Abstract Number: 509 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Disease Risk Factors May Negatively Impact Rheumatoid Arthritis Disease Outcomes: Findings from the Ontario Best Practices Research Initiative
Background/Purpose: Rheumatoid arthritis increases the risk of cardiovascular disease (CVD). Less is known about the direct influence of CVD on RA outcomes, but higher comorbidity…Abstract Number: 965 • 2018 ACR/ARHP Annual Meeting
Defining Cutoffs Corresponding to Low Levels of Disease Activity in Psoriatic Arthritis, Using the Patient-Reported Psoriatic Arthritis Impact of Disease Questionnaire (PsAID12). an Analysis of 436 Patients
Background/Purpose: The Psoriatic Arthritis (PsA) Impact of Disease questionnaire (PsAID12) score allows an assessment of patient-important symptoms and life impact in PsA. It is provisionally…
- « Previous Page
- 1
- …
- 64
- 65
- 66
- 67
- 68
- …
- 112
- Next Page »